Andera Partners

Andera Partners is a Paris-based private equity firm with a healthcare investment franchise that operates through its BioDiscovery family of funds. The firm finances breakthrough therapeutic programs from preclinical stages through commercialization across Europe, with portfolio examples including Agomab, a clinical-stage biopharmaceutical company developing therapeutics for fibrotic and inflammatory diseases. Andera’s healthcare practice is one of the more established European life-sciences investment platforms, with multiple BioDiscovery fund vintages and a partnership that has historically combined European life-sciences investing experience with operating depth in pharmaceutical development. The firm operates as a private equity rather than a pure venture capital investor, which signals both the size of its checks and the structure of its capital. Andera typically takes meaningful equity positions and often plays an active governance role in portfolio companies through board seats and operational engagement.

The healthcare investment thesis spans biotech, medical devices and medtech, and pharma and therapeutics, with a check size range of five to twenty-five million dollars and a stage focus running across Series A, Series B, Series C, and growth. The breadth across stages reflects the firm’s PE structure, which allows it to write checks from early clinical programs all the way through commercial-stage expansion capital. The therapeutic focus is genuine and central to the BioDiscovery thesis: Andera is particularly active in clinical-stage drug development and in medical device companies with European regulatory pathways. The firm is not AI-focused, and founders building AI-native digital health platforms or computational biology tools without a therapeutic or device component should look elsewhere. For founders building European biotech and medtech assets with rigorous clinical or regulatory milestones, Andera represents one of the deeper continental European investors capable of providing growth capital across multiple rounds.

The Agomab investment illustrates the kind of company Andera backs. Agomab works on therapies addressing fibrotic and inflammatory disease pathways and has progressed through multiple clinical milestones with European and international syndicate support. Beyond Agomab, this profile does not include a specific list of additional portfolio companies. Founders should consult Andera’s BioDiscovery portfolio pages and pay attention to which clinical-stage programs have advanced to pivotal trials versus which remain in earlier clinical phases, and to which medical device investments have completed CE marking and reimbursement milestones. The firm’s portfolio progression is the most reliable indicator of where its therapeutic conviction lies and which programs the partnership has continued to back across multiple capital rounds.

The five to twenty-five million dollar check size range and the breadth from Series A through growth rounds give Andera unusual flexibility in the European life-sciences capital stack. At early Series A, the firm typically participates as a meaningful institutional check alongside other European life-sciences specialists. At Series B and later, Andera is more likely to lead or co-lead rounds, particularly in clinical-stage programs requiring substantial capital to advance through pivotal trials. The firm’s growth-stage capability allows it to continue supporting portfolio companies through commercialization, which is valuable in a European biotech market where late-stage capital is often harder to assemble than in the United States. Andera syndicates frequently with other European life-sciences specialists, with strategic corporate venture arms of major pharmaceutical companies, and increasingly with US healthcare crossover funds when European biotech assets attract transatlantic interest.

Team member names are not enumerated in the source data for this profile. Founders should consult Andera’s website to identify the current BioDiscovery investing team and pay particular attention to partners with prior pharmaceutical operating experience, with prior medical device commercialization roles, or with academic clinical research backgrounds. Decision-making at Andera is partnership-driven with formal investment committee approval, and the partnership has historically been weighted toward partners with operating and scientific depth in life sciences. Founders should expect deep diligence on clinical strategy, on regulatory pathway, and on the team’s ability to execute against pivotal trial milestones.

The most reliable path into Andera Partners is a warm introduction from a portfolio founder, from a co-investor in European life sciences, or from a pharmaceutical industry executive with a prior relationship with the firm. The European biotech community is dense and partner-driven, and introductions through known channels carry significantly more weight than cold inbound. Founders coming out of European academic medical centers and biotech accelerators often find that their academic supervisors or clinical advisors can provide direct introductions to Andera’s BioDiscovery partners. Communication should be detailed and clinical, with deep engagement on mechanism, on trial design, and on regulatory strategy.

Founders should approach Andera Partners when they are building a clinical-stage therapeutics or medical device company in Europe, when they have meaningful preclinical or clinical data, and when they are raising Series A or later with a clear path to pivotal trial milestones. The firm is not the right fit for AI-native digital health platforms, for early-discovery programs without preclinical validation, or for non-therapeutic life-sciences software. It is an excellent fit for European biotech companies with breakthrough therapeutic programs, for medical device companies with substantive clinical and regulatory pathways, and for founders who value continental European capital depth and active governance support.